Multiple System Atrophy.

Area of Science:

• Neurology
• Neurodegenerative Disorders
• Autonomic Dysfunction

Background:

• Multiple system atrophy (MSA) is a rare, sporadic, adult-onset, progressive neurodegenerative disorder.
• Characterized by autonomic and motor dysfunction, MSA presents diagnostic challenges due to its complexity and similarity to other conditions.
• Accurate diagnosis relies on autonomic dysfunction, levodopa-resistant parkinsonism or cerebellar ataxia, neuroimaging, and excluding mimics.

Purpose of the Study:

• To provide up-to-date diagnosis and management concepts for multiple system atrophy (MSA).
• To summarize clinical best practices and emerging advances in MSA care.
• To highlight updated standards for diagnosing and managing MSA.

Main Methods:

• Review of current diagnostic criteria, including the 2022 International Parkinson and Movement Disorder Society criteria.
• Summary of symptomatic management strategies for parkinsonism, ataxia, and autonomic dysfunction.
• Discussion of advances in neuroimaging, molecular biomarkers, and potential disease-modifying agents.

Main Results:

• The 2022 criteria facilitate accurate and early diagnosis of MSA at various stages (established, probable, possible, and pathological).
• Current management focuses on symptomatic control using a multidisciplinary and multisystem approach, incorporating palliative care.
• Emerging research in brain imaging and biomarkers shows promise for improved diagnosis and treatment.

Conclusions:

• Updated diagnostic standards and a comprehensive, multidisciplinary approach are essential for managing multiple system atrophy (MSA).
• Continued research into advanced imaging, biomarkers, and disease-modifying therapies holds promise for future improvements in MSA care.
• Early and accurate diagnosis, coupled with tailored symptomatic management, remains critical for patients with this complex neurodegenerative disorder.